Incyte Corporation (INCY)
$111.36-1.27%Close
SELLBEAR · day 9
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $22.6B
- Beta
- 0.74
- P/E (TTM)
- 13.87
- Short % float
- 4.97%
- Days to cover
- 6.1
- SI change
- +0.1%
- 1W
- -2.43%
- 1M
- -8.32%
- vs SPY 1W
- -2.85%
- vs SPY 1M
- -10.38%
Industry peers
FMP comparable companies · ranked by market cap
- REGNSELLRegeneron Pharmaceuticals, Inc.$76.1BBEARQ 24$738.72+2.18%
- GMABBUYGenmab A/S$23.2BBULLQ 21$37.80+0.81%
- EXELBUYExelixis, Inc.$14.7BBULLQ 10$58.33-0.07%
- LGNDBUYLigand Pharmaceuticals Incorporated$6.0BRECOVERYQ 15$296.94+3.09%
- LEGNSELLLegend Biotech Corporation$3.5BRECOVERYQ 2$18.72-4.40%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.60-0.85%
- SLSSELLSELLAS Life Sciences Group, Inc.$2.1BRECOVERYQ -9$11.34+2.40%
- CGEMSELLCullinan Therapeutics, Inc.$999MCRISISQ 1$16.25-3.73%
- AVBPSELLArriVent BioPharma, Inc.$703MCRISISQ -6$15.09-1.61%
- VSTMBUYVerastem, Inc.$681MRECOVERYQ 4$7.75-1.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 54
- VALUE
- 47
- GROWTH
- 73
- GARP
- 20
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC17.8%
REV YoY-
ROE29.7%
EPS YoY-
ROA20.5%
GROSS93
OP32
NET28
[VALUATION]
P/E TTM13.87
P/E FWD15.07
SECTOR PE20.34
INDUSTRY PE13.84
P/B3.56
P/FCF-
EV/EBITDA9.26
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.60
ALTMAN Z-
CURR RATIO4.66
ND/EBITDA-
BETA0.74
Company news
FAQ
- What is LOPJLB’s current signal on INCY?
- LOPJLB’s latest quantitative signal on Incyte Corporation (INCY) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is INCY in?
- Incyte Corporation (INCY) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Incyte Corporation (INCY) do?
- Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inh…